Skip to content
Life Sciences Series A Founded 2013

AcuamarkDx

Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first…

📍 New York City, United States · Genomics,

Funding snapshot

Last roundSeries A
Amount$5M
Date22 May 2024
Total raised$20M
Team size8

About

Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer Founded in 2013, headquartered in New York City, United States. The company has raised $20M at the Series A stage backed by investors including Bruker, XLerateHealth. Operating in Life Sciences > Genomics, Life Sciences > Oncology.

Business model

Oncology > In-Vitro Diagnostic Tests > Gastrointestinal Cancer > Colorectal Cancer,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA and RNA

Institutional investors

Bruker XLerateHealth Claudio Del Vecchio

Latest coverage

No articles yet.

Raising like AcuamarkDx?

Analyze your pitch deck before your next raise.

Analyze My Deck →